Media & Press Updates
Visicell named a finalist at San Diego Angel Conference 2020
March 2, 2020
After an intense selection process, Visicell earned a spot to compete at the San Diego Angel Conference taking place on March 28. Six finalists will pitch to investors at this main event, with the top company taking home a minimum $200,000 investment.
Quarter-finalists announced for the 2nd annual San Diego Angel Conference
February 3, 2020
Visicell is one of twenty-seven companies advancing to the quarterfinal round of San Diego Angel Conference from a pool of more than 100 startup companies. The winning company will take home a guaranteed $200,000 investment from angels at the main event on March 28.
Visicell presents at California Institute of Regenerative Medicine
March 6, 2019
Visicell visited California Institute of Regenerative medicine (CIRM) and presented their recent development on non-invasive cell tracking technology. Learn more about CIRM and its patient-centered mission and impact using the link below.
Visicell is now part of Cell Therapy - TRAcking, Circulation, & Safety (CT-TRACS) Committee at HESI
February 28, 2019
Visicell had recently joined HESI CT-TRACS, a global committee with multiple stakeholders ranging from academic institutions, biotechnology/pharmaceutical companies, regulatory bodies, and other non-profit organizations across Americas, EU, and Asia. Visicell will work closely with other members of the committee such as Novartis, Beringer Manheim, Takeda, GE, Memorial Sloan Kettering, CIRM, and FDA…etc, to develop common best practices and standardize methods for evaluating the safety of cell therapy in patients
We always have a story to tell, so check our news section often and contact us if you need more information!